CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues

Biochemical and Biophysical Research Communications

Volumn 438, Issue 1, 2013, Pages 103-109

  Fujii, Masakazu ^a   Inoguchi, Toyoshi ^a,b   Batchuluun, Battsetseg ^a   Sugiyama, Naonobu ^a   Kobayashi, Kunihisa ^c   Sonoda, Noriyuki ^a,b   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Anti inflammation; Insulin resistance; Macrophage polarization; Obesity

Indexed keywords

ABATACEPT; ADIPONECTIN; APOPTOSIS INHIBITOR; ARGINASE 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOTHERAPY; INSULIN RESISTANCE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; POLARIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

AIM; ANTI-INFLAMMATION; APOPTOSIS INHIBITOR OF MACROPHAGE; AREA UNDER THE CURVE; AUC; CTLA-4LG; CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN-4IGG1; HFD; HIGH FAT DIET; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; IPGT; ITT; MACROPHAGE POLARIZATION; MCP; MONOCYTE CHEMOTACTIC PROTEIN; NCD; NORMAL CHOW DIET; OBESITY; RA; RHEUMATOID ARTHRITIS; STROMAL VASCULAR FRACTION; SVF;

ADIPOSE TISSUE; ANIMALS; CELL POLARITY; CTLA-4 ANTIGEN; IMMUNOTHERAPY; INSULIN RESISTANCE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OBESITY;

MUS;

EID: 84881543795     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.034     Document Type: Article

References (31)

1. Hubert H.B., Feinleib M., McNamara P.M., et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983, 67:968-977.
2. Nomiyama T., Perez-Tilve D., Ogawa D., et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 2007, 117:2877-2888.
3. Tabata M., Kadomatsu T., Fukuhara S., et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009, 10:178-188.
4. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43:1271-1278.
5. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
6. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
7. Mantovani A., Sica A., Sozzani S., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
8. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
9. Linsley P.S., Brady W., Grosmaire L., et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991, 173:721-730.
10. Linsley P.S., Greene J.L., Brady W., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
11. Peach R.J., Bajorath J., Brady W., et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 1994, 180:2049-2058.
12. Greene J.L., Leytze G.M., Emswiler J., et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 1996, 271:26762-26771.
13. Weisman M.H., Durez P., Hallegua D., et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J. Rheumatol. 2006, 33:2162-2166.
14. Buch M.H., Boyle D.L., Rosengren S., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 2009, 68:1220-1227.
15. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
16. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998, 83:847-850.
17. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005, 353:1114-1123.
18. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 2003, 112:1785-1788.
19. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
20. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
21. Arai S., Shelton J.M., Chen M., et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005, 1:201-213.
22. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
23. Kurokawa J., Arai S., Nakashima K., et al. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 2010, 11:479-492.
24. Tamori Y., Masugi J., Nishino N., et al. Role of peroxisome proliferator-activated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002, 51:2045-2055.
25. Coughlin C.C., Finck B.N., Eagon J.C., et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring) 2007, 15:640-645.
26. Altomonte J., Harbaran S., Richter A., et al. Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats. Metabolism 2003, 52:958-963.
27. Lihn A.S., Bruun J.M., He G., et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol. Cell. Endocrinol. 2004, 219:9-15.
28. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
29. Bruun J.M., Lihn A.S., Verdich C., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E527-E533.
30. Fasshauer M., Klein J., Neumann S., et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2002, 290:1084-1089.
31. Fasshauer M., Kralisch S., Klier M., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003, 301:1045-1050.